Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday.

Unlike BioNTech, Moderna's pipeline is nearly "all in" on mRNA assets. Most of them are infectious disease vaccines, particularly in COVID, flu, and RSV.

BioNTech SE BNTX and Moderna Inc MRNA are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic. Also Read: FDA Approves Updated ...

Moderna said it filed patents from 2010 to 2016 for its mRNA technology, which was critical in the company's creation of its own Covid vaccine. The company alleges that Pfizer and BioNTech then ...

Moderna stock popped 11.7% to 47.53, while BioNTech shares 5.6% to 126.88. BioNTech stock is consolidating with a buy point at 131.49.

Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams.

Pfizer stock tumbled 4.7%, closing at 24.80, while shares of Moderna skidded 7.3%, ending the regular session at 36.85. Novavax reversed early losses and closed with a 1.4% gain, while BioNTech ...

On April 12, 2024, Judge Richard G. Stearns granted BioNTech and Pfizer’s motion to stay the district court litigation pending the resolution of IPR2023-01358 and IPR2023-01359.

MADRID—Moderna and BioNTech have quite a few things in common, one being that both are trying to chart their post-COVID course by reinventing cancer modalities. And both, it seems, have run into ...

Moderna sued them in 2022 for allegedly copying its messenger RNA technology. Pfizer and BioNTech, its German business partner, filed a countersuit, alleging that Moderna’s patent was invalid.

Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer treatment is one of the pharmaceutical industry’s biggest, most ...